Wednesday, October 23, 2013 2:45:13 AM
I agree with this and that's why I thought Risk's scenario was unlikely (to say the least). For me the funding that Mart Saarma received for studying MANF/DB is what is most interesting. I think we're all aware that he's not studying MANF/PD.
My question for you regarding the Biomarker Discovery Center's work on a blood test for AD has to do with it being ahead of Lympro. By 'ahead' do you mean that it's on target for commercialization ahead of 2H 2014? If not, in what way is it 'ahead'?
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM